Sjögren's disease & overlap diseases
Impact of IgG Fc Glycosylation on Disease Dynamics in Patients With Primary Sjögren Disease
Authors' conclusion
This study points to a novel role of IgG Fc glycosylation in patients with SjD in predicting disease transition, monitoring disease activity, and stratifying risk of NHL development.
Study context
- Population
- Suspected and confirmed primary Sjögren disease (SjD), Belgian Sjögren's Syndrome Transition Trial
- Participants
- 300 participants
- Exposure
- Primary SjD vs asymptomatic anti-SSA carriers and patients with sicca
- Outcome
- IgG Fc sialylation and galactosylation levels
Main finding
As reported in the abstract
- SjD had significantly lower sialylation and galactosylation levels vs asymptomatic carriers of anti-SSA and sicca
- Lower sialylation and galactosylation significantly associated with increased B cell activation markers and distinct autoantibody profiles, particularly multiple autoantibody reactivities
- Lower levels also linked to histopathological salivary gland alterations, higher Hocevar scores and risk factors for non-Hodgkin lymphoma (NHL) development
- Mono-anti-Ro60 positive and anti-SSA negative SjD had normal IgG Fc glycosylation
Observational data: associations, not effects.
Original publication
Impact of IgG Fc Glycosylation on Disease Dynamics in Patients With Primary Sjögren Disease. Arthritis Rheumatol. Published 11 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →